title: The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
abstract: We aimed to examine the blood pressure (BP)-lowering effect and the time to attain the maximal antihypertensive effect (stabilization time) of several angiotensin II receptor blockers (ARBs) based on home BP measurements.
  
  
  
  We surveyed consecutive newly diagnosed, untreated patients with hypertension who started the treatment with a mid-level dose of one of seven ARBs (losartan 50 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, valsartan 80 mg, irbesartan 100 mg, or azilsartan 20 mg). All study participants measured home BP in the morning for at least 1 week during an untreated period and 4 weeks during the treatment period.
  
  
  
  Age, the proportion of men, and baseline home BP levels did not differ significantly between groups (total n = 232; age, 62.2 years; 50.9% men; home SBP/DBP, 151.6/90.0 mmHg). Significant differences in the BP-lowering effect and the stabilization time between ARBs were observed (P ≤ 0.02). The extent of BP-lowering effects of azilsartan 20 mg was significantly greater than that of valsartan 80 mg or irbesartan 100 mg (15.3 vs. 7.9 or 8.2 mmHg, respectively P ≤ 0.03). The stabilization time of losartan for home SBP was significantly longer than that of valsartan, irbesartan, or azilsartan (22.8 vs. 7.1, 4.7, or 7.1 days, respectively, P ≤ 0.01).
  
  
  
  The maximum effect and the stabilization time differed among ARBs used at the mid-level dose in Japan. An ARB should be chosen based on its desired characteristics.
authors.affiliation: aDepartment of Pharmaceutical Sciences, Tohoku University Hospital bDepartment of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences cDepartment of Preventive Medicine and Epidemiology dDepartment of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University eDivision of Aging and Geriatric Dentistry, Tohoku University Graduate School of Dentistry fMedical Information Technology Center, Tohoku University Hospital, Sendai gDepartment of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.
authors.forename: Michihiro
authors.initials: M
authors.lastname: Satoh
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Haga
authors.forename: Miki
authors.initials: M
authors.lastname: Hosaka
authors.forename: Taku
authors.initials: T
authors.lastname: Obara
authors.forename: Hirohito
authors.initials: H
authors.lastname: Metoki
authors.forename: Takahisa
authors.initials: T
authors.lastname: Murakami
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kikuya
authors.forename: Ryusuke
authors.initials: R
authors.lastname: Inoue
authors.forename: Kei
authors.initials: K
authors.lastname: Asayama
authors.forename: Nariyasu
authors.initials: N
authors.lastname: Mano
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Ohkubo
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Imai
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000494:pharmacology; D000077405:Irbesartan; D019808:Losartan / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010069:Oxadiazoles / Q000494:pharmacology; D012648:Self Care; D000077333:Telmisartan; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors; D000068756:Valsartan / Q000494:pharmacology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D007093:Imidazoles; D010069:Oxadiazoles; D013777:Tetrazoles; D000068756:Valsartan; C437965:olmesartan; C521273:azilsartan; D000077405:Irbesartan; D019808:Losartan; C081643:candesartan; D000077333:Telmisartan